Literature DB >> 32291795

Sustainability of costs of novel biologicals: Are we all heading for bankruptcy?

Robert Likic1,2.   

Abstract

Mesh：

Substances：

Year:  2020        PMID： 32291795      PMCID： PMC7318998          DOI： 10.1111/bcp.14295

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  13 in total

1.  Tools for Taking the Measure Of Cancer Drugs.

Authors:  Ed Silverman
Journal:  Manag Care       Date:  2015-07

2.  Budget Impact Analysis of Biosimilar Trastuzumab for the Treatment of Breast Cancer in Croatia.

Authors:  August Cesarec; Robert Likić
Journal:  Appl Health Econ Health Policy       Date:  2017-04       Impact factor: 2.561

3.  Jobs come under threat at troubled Karolinska hospital in Sweden.

Authors:  Marta Paterlini
Journal:  BMJ       Date:  2019-11-12

Review 4.  Saving orphan drug legislations: misconceptions and clarifications.

Authors:  Hanna I Hyry; Timothy M Cox; Jonathan C P Roos
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2016       Impact factor: 2.217

Review 5.  Affordable orphan drugs: a role for not-for-profit organizations.

Authors:  Elin H Davies; Emma Fulton; Daniel Brook; Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2017-02-08       Impact factor: 4.335

Review 6.  Pharmaceutical policies: effects of financial incentives for prescribers.

Authors:  Arash Rashidian; Amir-Houshang Omidvari; Yasaman Vali; Heidrun Sturm; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2015-08-04

7.  Negotiating prices of drugs for rare diseases.

Authors:  Séverine Henrard; Francis Arickx
Journal:  Bull World Health Organ       Date:  2016-08-31       Impact factor: 9.408

Review 8.  Addressing the challenge of high-priced prescription drugs in the era of precision medicine: A systematic review of drug life cycles, therapeutic drug markets and regulatory frameworks.

Authors:  Toon van der Gronde; Carin A Uyl-de Groot; Toine Pieters
Journal:  PLoS One       Date:  2017-08-16       Impact factor: 3.240

Review 9.  Pharmaceutical policies: effects of reference pricing, other pricing, and purchasing policies.

Authors:  Angela Acosta; Agustín Ciapponi; Morten Aaserud; Valeria Vietto; Astrid Austvoll-Dahlgren; Jan Peter Kösters; Claudia Vacca; Manuel Machado; Diana Hazbeydy Diaz Ayala; Andrew D Oxman
Journal:  Cochrane Database Syst Rev       Date:  2014-10-16

10.  Biosimilars: How Can Payers Get Long-Term Savings?

Authors:  Jorge Mestre-Ferrandiz; Adrian Towse; Mikel Berdud
Journal:  Pharmacoeconomics       Date:  2016-06       Impact factor: 4.981
View more
  1 in total

1.  Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective.

Authors:  Pekka Kurki; Sean Barry; Ingrid Bourges; Panagiota Tsantili; Elena Wolff-Holz
Journal:  Drugs       Date:  2021-10-01       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.